glp-1 drugs how do they work Receptor Agonists as Treatments for Type 2 Diabetes Evolution of GLP‐1 Receptor Agonists

Kinzig, K

In a study using cultured rat hippocampal neurons, pre-treatment of nerve cells with GLP-1 resulted in a weakened Ca 2+ response to glutamate and weakened membrane depolarization ( Effects on Parkinsons Disease Parkinsons disease (PD) is a chronic neurodegenerative disease that affects the central nervous system and the second most common neurodegenerative disease after AD (56)

There were no serious or severe adverse events (AEs) reported, nor discontinuations due to AEs (Table S10)

56 After 3 years, the primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, or CV death) occurred in fewer patients assigned to the SGLT2-I versus placebo (10.5% vs 12.1%

You don't need a diabetes diagnosis to benefit from GLP-1 medications

Extensive research over the past decade has provided evidence that GLP-1 receptor agonists do not appear to increase the risk of pancreatic cancer